Skip to main content
Signal8
Launch Terminal

RetinalGenix Technologies Inc. (RTGN)

RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

RetinalGenix Technologies Inc. logo

RetinalGenix Technologies Inc.

OTC:RTGNHealthcare
Mkt Cap-
Float6.25M
O/S-
Inst Own-
Dilution
RetinalGenix Technologies Inc. logoOTC:RTGN
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--
SectorHealthcare
IndustryMedical - Devices
ExchangeOTC
CountryUSUS
IPO Date-
Shares Outstanding-
Float6.25M
Company Overview

RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology.

Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients.

Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners.

The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.

Leadership

Jerry Katzman

Chief Executive Officer, President, Interim Chief Financial Officer & Chairman

Employees

--

Country

US

Sector

Healthcare

Website

retinalgenix.com

Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
--
Institutional
(0)
--
Insiderⓘ
(0)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Sources:
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

667

90d Avg

667

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...